The global Drug-Device Combination Products market size is predicted to grow from US$ 41780 million in 2025 to US$ 60740 million in 2031; it is expected to grow at a CAGR of 6.4% from 2025 to 2031.
Combination products are therapeutic and diagnostic products that combine drugs, devices and/or biological products, leading to safer and more effective treatments thanks to careful and precise drug targeting, local administration and individualized therapy. These technologies can especially benefit patients suffering from serious diseases and conditions such as cancer, heart disease, multiple sclerosis and diabetes, among others. On the other hand, drug-device combination products have also introduced a new dynamic in medical product development, regulatory approval and corporate interaction.
Drivers of the Drug-Device Combination Products Market:
Growing Prevalence of Chronic Diseases: The rising incidence of chronic conditions such as diabetes, cardiovascular diseases, and respiratory disorders is fueling demand for drug-device combination products. These products, which combine medications with devices (like insulin pens or inhalers), offer more effective and patient-friendly treatment options.
Technological Advancements: Innovations in drug delivery technologies (e.g., smart drug delivery systems, micro-needles, and wearable injectors) have enhanced the efficiency and convenience of combination products. These innovations improve patient compliance and the precision of drug administration, driving market growth.
Increasing Geriatric Population: The global rise in the elderly population leads to greater demand for combination products. The elderly are more likely to suffer from multiple chronic conditions that require complex treatment regimes, which are often easier to manage with combination products.
Shift to Self-administration: Drug-device combination products enable patients to administer their medication at home, reducing the need for frequent hospital visits. This trend is particularly relevant during public health crises, like the COVID-19 pandemic, and supports growth in this market.
Regulatory Support: Regulatory authorities such as the FDA have provided specific pathways and guidance for the approval of drug-device combination products. This clarity supports product development and market entry.
Challenges in the Drug-Device Combination Products Market:
Complex Regulatory Approval Process: Despite some regulatory support, obtaining approval for drug-device combination products can be challenging. These products must meet both drug and device regulations, leading to potentially longer approval times and higher costs.
High Development Costs: The integration of drugs and devices often requires substantial investment in research, development, and clinical trials. This can be a barrier for smaller companies or startups trying to enter the market.
Risk of Product Recalls: Combination products are subject to the risks associated with both drugs and devices, such as manufacturing defects, quality issues, and adverse events. A problem with one component can lead to recalls, damaging a company鈥檚 reputation and finances.
Reimbursement and Pricing Issues: Securing reimbursement for combination products can be complex due to their dual nature. Payers may not readily classify or cover these products under standard reimbursement schemes, creating pricing challenges.
Patient Education and Compliance: Despite the benefits of self-administration, patients may struggle with proper use of combination products, leading to poor outcomes or misuse. Ensuring that patients are adequately educated about their use is a significant challenge.
Global key drug-device combination products players include GSK, Novo Nordisk and Eli Lilly etc. The top 3 companies hold a share about 32%. North America is the largset market with a share about 42%, followed by Europe and Asia-Pacific. In terms of product, nebulizer & inhaler is the largest segment with a share about 36%. And in terms of applications, the largset application is hospital and clinic with a share about 47%.
The 鈥淒rug-Device Combination Products Industry Forecast鈥� looks at past sales and reviews total world Drug-Device Combination Products sales in 2024, providing a comprehensive analysis by region and market sector of projected Drug-Device Combination Products sales for 2025 through 2031. With Drug-Device Combination Products sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Drug-Device Combination Products industry.
This Insight Report provides a comprehensive analysis of the global Drug-Device Combination Products landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Drug-Device Combination Products portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Drug-Device Combination Products market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Drug-Device Combination Products and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Drug-Device Combination Products.
This report presents a comprehensive overview, market shares, and growth opportunities of Drug-Device Combination Products market by product type, application, key players and key regions and countries.
Segmentation by Type:
Drug-Coated Device
Prefilled Drug Delivery Systems
Nebulizer and Inhaler
Transdermal Delivery System
Others
Segmentation by Application:
Hospital andClinic
Retail Pharmacies
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
GSK
Novo Nordisk
Eli Lilly
AstraZeneca
Sanofi
Boston Scientific
Abbott
Boehringer Ingelheim
Medtronic
Viatris
3M
Hisamitsu
Smith & Nephew
Molnlycke
Teleflex
BD
Lepu Medical
MicroPort
Terumo
B. Braun
Antares Pharma
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Drug-Device Combination Products Market Size (2020-2031)
2.1.2 Drug-Device Combination Products Market Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Drug-Device Combination Products by Country/Region (2020, 2024 & 2031)
2.2 Drug-Device Combination Products Segment by Type
2.2.1 Drug-Coated Device
2.2.2 Prefilled Drug Delivery Systems
2.2.3 Nebulizer and Inhaler
2.2.4 Transdermal Delivery System
2.2.5 Others
2.3 Drug-Device Combination Products Market Size by Type
2.3.1 Drug-Device Combination Products Market Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Drug-Device Combination Products Market Size Market Share by Type (2020-2025)
2.4 Drug-Device Combination Products Segment by Application
2.4.1 Hospital andClinic
2.4.2 Retail Pharmacies
2.4.3 Other
2.5 Drug-Device Combination Products Market Size by Application
2.5.1 Drug-Device Combination Products Market Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Drug-Device Combination Products Market Size Market Share by Application (2020-2025)
3 Drug-Device Combination Products Market Size by Player
3.1 Drug-Device Combination Products Market Size Market Share by Player
3.1.1 Global Drug-Device Combination Products Revenue by Player (2020-2025)
3.1.2 Global Drug-Device Combination Products Revenue Market Share by Player (2020-2025)
3.2 Global Drug-Device Combination Products Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Drug-Device Combination Products by Region
4.1 Drug-Device Combination Products Market Size by Region (2020-2025)
4.2 Global Drug-Device Combination Products Annual Revenue by Country/Region (2020-2025)
4.3 Americas Drug-Device Combination Products Market Size Growth (2020-2025)
4.4 APAC Drug-Device Combination Products Market Size Growth (2020-2025)
4.5 Europe Drug-Device Combination Products Market Size Growth (2020-2025)
4.6 Middle East & Africa Drug-Device Combination Products Market Size Growth (2020-2025)
5 Americas
5.1 Americas Drug-Device Combination Products Market Size by Country (2020-2025)
5.2 Americas Drug-Device Combination Products Market Size by Type (2020-2025)
5.3 Americas Drug-Device Combination Products Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Drug-Device Combination Products Market Size by Region (2020-2025)
6.2 APAC Drug-Device Combination Products Market Size by Type (2020-2025)
6.3 APAC Drug-Device Combination Products Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Drug-Device Combination Products Market Size by Country (2020-2025)
7.2 Europe Drug-Device Combination Products Market Size by Type (2020-2025)
7.3 Europe Drug-Device Combination Products Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Drug-Device Combination Products by Region (2020-2025)
8.2 Middle East & Africa Drug-Device Combination Products Market Size by Type (2020-2025)
8.3 Middle East & Africa Drug-Device Combination Products Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Drug-Device Combination Products Market Forecast
10.1 Global Drug-Device Combination Products Forecast by Region (2026-2031)
10.1.1 Global Drug-Device Combination Products Forecast by Region (2026-2031)
10.1.2 Americas Drug-Device Combination Products Forecast
10.1.3 APAC Drug-Device Combination Products Forecast
10.1.4 Europe Drug-Device Combination Products Forecast
10.1.5 Middle East & Africa Drug-Device Combination Products Forecast
10.2 Americas Drug-Device Combination Products Forecast by Country (2026-2031)
10.2.1 United States Market Drug-Device Combination Products Forecast
10.2.2 Canada Market Drug-Device Combination Products Forecast
10.2.3 Mexico Market Drug-Device Combination Products Forecast
10.2.4 Brazil Market Drug-Device Combination Products Forecast
10.3 APAC Drug-Device Combination Products Forecast by Region (2026-2031)
10.3.1 China Drug-Device Combination Products Market Forecast
10.3.2 Japan Market Drug-Device Combination Products Forecast
10.3.3 Korea Market Drug-Device Combination Products Forecast
10.3.4 Southeast Asia Market Drug-Device Combination Products Forecast
10.3.5 India Market Drug-Device Combination Products Forecast
10.3.6 Australia Market Drug-Device Combination Products Forecast
10.4 Europe Drug-Device Combination Products Forecast by Country (2026-2031)
10.4.1 Germany Market Drug-Device Combination Products Forecast
10.4.2 France Market Drug-Device Combination Products Forecast
10.4.3 UK Market Drug-Device Combination Products Forecast
10.4.4 Italy Market Drug-Device Combination Products Forecast
10.4.5 Russia Market Drug-Device Combination Products Forecast
10.5 Middle East & Africa Drug-Device Combination Products Forecast by Region (2026-2031)
10.5.1 Egypt Market Drug-Device Combination Products Forecast
10.5.2 South Africa Market Drug-Device Combination Products Forecast
10.5.3 Israel Market Drug-Device Combination Products Forecast
10.5.4 Turkey Market Drug-Device Combination Products Forecast
10.6 Global Drug-Device Combination Products Forecast by Type (2026-2031)
10.7 Global Drug-Device Combination Products Forecast by Application (2026-2031)
10.7.1 GCC Countries Market Drug-Device Combination Products Forecast
11 Key Players Analysis
11.1 GSK
11.1.1 GSK Company Information
11.1.2 GSK Drug-Device Combination Products Product Offered
11.1.3 GSK Drug-Device Combination Products Revenue, Gross Margin and Market Share (2020-2025)
11.1.4 GSK Main Business Overview
11.1.5 GSK Latest Developments
11.2 Novo Nordisk
11.2.1 Novo Nordisk Company Information
11.2.2 Novo Nordisk Drug-Device Combination Products Product Offered
11.2.3 Novo Nordisk Drug-Device Combination Products Revenue, Gross Margin and Market Share (2020-2025)
11.2.4 Novo Nordisk Main Business Overview
11.2.5 Novo Nordisk Latest Developments
11.3 Eli Lilly
11.3.1 Eli Lilly Company Information
11.3.2 Eli Lilly Drug-Device Combination Products Product Offered
11.3.3 Eli Lilly Drug-Device Combination Products Revenue, Gross Margin and Market Share (2020-2025)
11.3.4 Eli Lilly Main Business Overview
11.3.5 Eli Lilly Latest Developments
11.4 AstraZeneca
11.4.1 AstraZeneca Company Information
11.4.2 AstraZeneca Drug-Device Combination Products Product Offered
11.4.3 AstraZeneca Drug-Device Combination Products Revenue, Gross Margin and Market Share (2020-2025)
11.4.4 AstraZeneca Main Business Overview
11.4.5 AstraZeneca Latest Developments
11.5 Sanofi
11.5.1 Sanofi Company Information
11.5.2 Sanofi Drug-Device Combination Products Product Offered
11.5.3 Sanofi Drug-Device Combination Products Revenue, Gross Margin and Market Share (2020-2025)
11.5.4 Sanofi Main Business Overview
11.5.5 Sanofi Latest Developments
11.6 Boston Scientific
11.6.1 Boston Scientific Company Information
11.6.2 Boston Scientific Drug-Device Combination Products Product Offered
11.6.3 Boston Scientific Drug-Device Combination Products Revenue, Gross Margin and Market Share (2020-2025)
11.6.4 Boston Scientific Main Business Overview
11.6.5 Boston Scientific Latest Developments
11.7 Abbott
11.7.1 Abbott Company Information
11.7.2 Abbott Drug-Device Combination Products Product Offered
11.7.3 Abbott Drug-Device Combination Products Revenue, Gross Margin and Market Share (2020-2025)
11.7.4 Abbott Main Business Overview
11.7.5 Abbott Latest Developments
11.8 Boehringer Ingelheim
11.8.1 Boehringer Ingelheim Company Information
11.8.2 Boehringer Ingelheim Drug-Device Combination Products Product Offered
11.8.3 Boehringer Ingelheim Drug-Device Combination Products Revenue, Gross Margin and Market Share (2020-2025)
11.8.4 Boehringer Ingelheim Main Business Overview
11.8.5 Boehringer Ingelheim Latest Developments
11.9 Medtronic
11.9.1 Medtronic Company Information
11.9.2 Medtronic Drug-Device Combination Products Product Offered
11.9.3 Medtronic Drug-Device Combination Products Revenue, Gross Margin and Market Share (2020-2025)
11.9.4 Medtronic Main Business Overview
11.9.5 Medtronic Latest Developments
11.10 Viatris
11.10.1 Viatris Company Information
11.10.2 Viatris Drug-Device Combination Products Product Offered
11.10.3 Viatris Drug-Device Combination Products Revenue, Gross Margin and Market Share (2020-2025)
11.10.4 Viatris Main Business Overview
11.10.5 Viatris Latest Developments
11.11 3M
11.11.1 3M Company Information
11.11.2 3M Drug-Device Combination Products Product Offered
11.11.3 3M Drug-Device Combination Products Revenue, Gross Margin and Market Share (2020-2025)
11.11.4 3M Main Business Overview
11.11.5 3M Latest Developments
11.12 Hisamitsu
11.12.1 Hisamitsu Company Information
11.12.2 Hisamitsu Drug-Device Combination Products Product Offered
11.12.3 Hisamitsu Drug-Device Combination Products Revenue, Gross Margin and Market Share (2020-2025)
11.12.4 Hisamitsu Main Business Overview
11.12.5 Hisamitsu Latest Developments
11.13 Smith & Nephew
11.13.1 Smith & Nephew Company Information
11.13.2 Smith & Nephew Drug-Device Combination Products Product Offered
11.13.3 Smith & Nephew Drug-Device Combination Products Revenue, Gross Margin and Market Share (2020-2025)
11.13.4 Smith & Nephew Main Business Overview
11.13.5 Smith & Nephew Latest Developments
11.14 Molnlycke
11.14.1 Molnlycke Company Information
11.14.2 Molnlycke Drug-Device Combination Products Product Offered
11.14.3 Molnlycke Drug-Device Combination Products Revenue, Gross Margin and Market Share (2020-2025)
11.14.4 Molnlycke Main Business Overview
11.14.5 Molnlycke Latest Developments
11.15 Teleflex
11.15.1 Teleflex Company Information
11.15.2 Teleflex Drug-Device Combination Products Product Offered
11.15.3 Teleflex Drug-Device Combination Products Revenue, Gross Margin and Market Share (2020-2025)
11.15.4 Teleflex Main Business Overview
11.15.5 Teleflex Latest Developments
11.16 BD
11.16.1 BD Company Information
11.16.2 BD Drug-Device Combination Products Product Offered
11.16.3 BD Drug-Device Combination Products Revenue, Gross Margin and Market Share (2020-2025)
11.16.4 BD Main Business Overview
11.16.5 BD Latest Developments
11.17 Lepu Medical
11.17.1 Lepu Medical Company Information
11.17.2 Lepu Medical Drug-Device Combination Products Product Offered
11.17.3 Lepu Medical Drug-Device Combination Products Revenue, Gross Margin and Market Share (2020-2025)
11.17.4 Lepu Medical Main Business Overview
11.17.5 Lepu Medical Latest Developments
11.18 MicroPort
11.18.1 MicroPort Company Information
11.18.2 MicroPort Drug-Device Combination Products Product Offered
11.18.3 MicroPort Drug-Device Combination Products Revenue, Gross Margin and Market Share (2020-2025)
11.18.4 MicroPort Main Business Overview
11.18.5 MicroPort Latest Developments
11.19 Terumo
11.19.1 Terumo Company Information
11.19.2 Terumo Drug-Device Combination Products Product Offered
11.19.3 Terumo Drug-Device Combination Products Revenue, Gross Margin and Market Share (2020-2025)
11.19.4 Terumo Main Business Overview
11.19.5 Terumo Latest Developments
11.20 B. Braun
11.20.1 B. Braun Company Information
11.20.2 B. Braun Drug-Device Combination Products Product Offered
11.20.3 B. Braun Drug-Device Combination Products Revenue, Gross Margin and Market Share (2020-2025)
11.20.4 B. Braun Main Business Overview
11.20.5 B. Braun Latest Developments
11.21 Antares Pharma
11.21.1 Antares Pharma Company Information
11.21.2 Antares Pharma Drug-Device Combination Products Product Offered
11.21.3 Antares Pharma Drug-Device Combination Products Revenue, Gross Margin and Market Share (2020-2025)
11.21.4 Antares Pharma Main Business Overview
11.21.5 Antares Pharma Latest Developments
12 Research Findings and Conclusion
听
听
*If Applicable.
